- Home
- CUE vs CTOR Comparison
CUE vs CTOR Comparison
Compare CUE & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- CTOR
- Stock Information
- Founded
- CUE 2014
- CTOR 2021
- Country
- CUE United States
- CTOR United States
- Employees
- CUE N/A
- CTOR N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- CTOR
- Sector
- CUE Health Care
- CTOR
- Exchange
- CUE Nasdaq
- CTOR NYSE
- Market Cap
- CUE 91.9M
- CTOR 89.9M
- IPO Year
- CUE 2018
- CTOR N/A
- Fundamental
- Price
- CUE $1.49
- CTOR $1.25
- Analyst Decision
- CUE Strong Buy
- CTOR Strong Buy
- Analyst Count
- CUE 5
- CTOR 2
- Target Price
- CUE $5.00
- CTOR $4.50
- AVG Volume (30 Days)
- CUE 254.0K
- CTOR 68.9K
- Earning Date
- CUE 03-10-2025
- CTOR 02-14-2025
- Dividend Yield
- CUE N/A
- CTOR N/A
- EPS Growth
- CUE N/A
- CTOR N/A
- EPS
- CUE N/A
- CTOR N/A
- Revenue
- CUE $9,532,000.00
- CTOR N/A
- Revenue This Year
- CUE $73.11
- CTOR N/A
- Revenue Next Year
- CUE $11.02
- CTOR N/A
- P/E Ratio
- CUE N/A
- CTOR N/A
- Revenue Growth
- CUE 149.53
- CTOR N/A
- 52 Week Low
- CUE $0.45
- CTOR $0.85
- 52 Week High
- CUE $2.37
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- CUE 58.61
- CTOR N/A
- Support Level
- CUE $1.22
- CTOR N/A
- Resistance Level
- CUE $1.50
- CTOR N/A
- Average True Range (ATR)
- CUE 0.12
- CTOR 0.00
- MACD
- CUE 0.00
- CTOR 0.00
- Stochastic Oscillator
- CUE 96.67
- CTOR 0.00
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.